Roberta Di Marsico
Overview
Explore the profile of Roberta Di Marsico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
158
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pestrin M, Bessi S, Puglisi F, Minisini A, Masci G, Battelli N, et al.
Breast Cancer Res Treat
. 2012 Apr;
134(1):283-9.
PMID: 22476856
This multicenter phase II trial was designed to evaluate the activity of lapatinib in metastatic breast cancer patients with HER2-negative primary tumors and HER2-positive circulating tumor cells (CTCs). In this...
2.
Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al.
Clin Cancer Res
. 2009 Jul;
15(15):4954-62.
PMID: 19622584
Purpose: The aims of the present study were to evaluate the clinical activity and the pharmacodynamic profile of the novel schedule of a single i.v. standard dose of cyclophosphamide (CTX)...
3.
Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan A, Nannizzi S, et al.
Clin Cancer Res
. 2008 Mar;
14(6):1797-803.
PMID: 18347182
Purpose: Selecting patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in non-small cell lung cancer (NSCLC). Polymorphisms at the xeroderma pigmentosum group D...
4.
Martella F, Giannessi P, Di Marsico R, Coltelli L, Safina V, Giuntini N, et al.
Tumori
. 2007 Jun;
93(2):145-9.
PMID: 17557560
Aims And Background: Docetaxel is an active agent in metastatic cancers. The standard administration every 3 weeks frequently causes gastrointestinal toxicity and severe myelosuppression. These are rare with a weekly...
5.
Allegrini G, Falcone A, Di Marsico R, Lencioni M, Masi G, Galli C, et al.
Am J Clin Oncol
. 2004 Feb;
27(1):101-5.
PMID: 14758142
The main objective of this study was to determine the feasibility and the antitumor activity of a chemotherapy regimen with a 48-hour infusion of 5-fluorouracil (5-FU), leucovorin (LV), cisplatin (CDDP),...